Johnson Lin

Johnson Lin is publicly identified as a Partner at WI Harper Group, a cross-border venture capital firm founded in 1993 and known as one of the early venture firms active in Greater China. WI Harper says it has backed hundreds of companies, manages more than $1 billion in committed capital, and invests from offices in San Francisco, Taipei, and Beijing.

Lin was described in a September 2017 XW Laboratories financing announcement as “Healthcare Partner at WI Harper,” where he commented on WI Harper’s co-led $17.5 million Series B investment in XW Labs. In that role, he was associated with healthcare and biopharmaceutical investing, particularly companies addressing drug affordability, delivery, and clinical development.

In August 2020, during Hong Kong Science and Technology Parks’ Global Matching 2020 program, South China Morning Post identified Lin as a Partner at WI Harper Group. In that interview, he discussed how Covid-19 was changing venture interest toward e-commerce, telemedicine, biotech, sustainability, alternative plastics, gene editing, and respiratory medical technology.

WI Harper’s current public team page does not list Johnson Lin among current team members, so his current operating status at the firm could not be independently confirmed from the firm website. No reliable public education history was found in the sources reviewed.

• Invests through WI Harper’s broader early-stage and expansion-stage venture model, focused on companies with China or Greater China operations or relevance and global growth potential.
• Healthcare focus includes companies that can improve value for patients and payers. In the XW Labs Series B announcement, Lin said: “Affordability in pharmaceutical products is a major problem.”
• In biopharma, Lin highlighted XW Labs’ work on “optimizing delivery and functional profiles,” suggesting interest in drug-development platforms that can improve safety, efficacy, delivery, or cost.
• During Covid-19, Lin said venture opportunities were increasing in e-commerce, telemedicine, biotech, sustainability, alternative plastics, gene editing, and respiratory medical technology.
• WI Harper’s broader stated approach is to invest where the firm can add value through financing, operational guidance, strategic partnerships, executive support, networks, and market expansion.